Drugs / IL-12 GEMys
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07672483 | Oct 2026 → Jan 2028 expected | cancer or benign tumor | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IL-12 GEMys | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07672483 ↗ |
| Action | Activate | “Researchers want to know if myeloid cells that have been genetically engineered to produce IL-12 (IL-12 GEMys) can activate the immune system to attack cancer cells in solid tumors.” NCT07672483 ↗ |
| Modality | Cell therapy | “Cell therapy generated from autologous CD34+ cells.” NCT07672483 ↗ |
| Route | Intravenous | “Administered on Day 0 as an IV infusion” NCT07672483 ↗ |